Novavax (FRA:NVV1) E10: €-9.31 (As of Mar. 2026)


FRA:NVV1 Novavax Inc FRA:NVV1
50 GF Score
Price €8.02
GF Value €3.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax E10?

Novavax FRA:NVV1 -2.08% 50 E10 is €-9.31 as of Mar. 2026. GuruFocus rates FRA:NVV1 with a GF Score™ of 50/100 and a GF Value™ of €3.26 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novavax's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.052. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-9.31 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 4.70% per year. During the past 5 years, the average E10 Growth Rate was -3.20% per year. During the past 10 years, the average E10 Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novavax was 11.20% per year. The lowest was -12.00% per year. And the median was -0.65% per year.

As of today (2026-07-08), Novavax's current stock price is €8.02. Novavax's E10 for the quarter that ended in Mar. 2026 was €-9.31. Novavax's Shiller PE Ratio of today is .


Novavax  (FRA:NVV1) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novavax E10 Related Terms


Novavax E10 Historical Data

* Premium members only.

The historical data trend for Novavax's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax E10 Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.37 -11.57 -12.45 -12.70 -9.86

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.78 -10.79 -10.51 -9.86 -9.31

FRA:NVV1 vs MPLT, COAG, INBX: E10 Comparison

For the Biotechnology subindustry, Novavax's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Shiller PE Ratio falls into.


FRA:NVV1
50GF Score
Novavax Inc FRA:NVV1
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.052/330.2130*330.2130
=-0.052

Current CPI (Mar. 2026) = 330.2130.

Novavax Quarterly Data

per share eps CPI Adj_EPS
201606 -5.162 241.018 -7.072
201609 -4.277 241.428 -5.850
201612 -3.982 241.432 -5.446
201703 -2.992 243.801 -4.052
201706 -2.848 244.955 -3.839
201709 -2.525 246.819 -3.378
201712 -2.704 246.524 -3.622
201803 -2.271 249.554 -3.005
201806 -2.029 251.989 -2.659
201809 -1.997 252.439 -2.612
201812 -2.285 251.233 -3.003
201903 -1.867 254.202 -2.425
201906 -1.496 256.143 -1.929
201909 -0.672 256.759 -0.864
201912 -1.017 256.974 -1.307
202003 -0.525 258.115 -0.672
202006 -0.266 257.797 -0.341
202009 -2.725 260.280 -3.457
202012 -2.219 260.474 -2.813
202103 -2.562 264.877 -3.194
202106 -3.943 271.696 -4.792
202109 -3.664 274.310 -4.411
202112 -9.894 278.802 -11.718
202203 2.324 287.504 2.669
202206 -6.177 296.311 -6.884
202209 -2.172 296.808 -2.416
202212 -2.152 296.797 -2.394
202303 -3.185 301.836 -3.484
202306 0.535 305.109 0.579
202309 -1.181 307.789 -1.267
202312 -1.348 306.746 -1.451
202403 -0.966 312.332 -1.021
202406 0.920 314.175 0.967
202409 -0.685 315.301 -0.717
202412 -0.487 315.605 -0.510
202503 2.710 319.799 2.798
202506 0.538 322.561 0.551
202509 -1.065 324.800 -1.083
202512 0.094 324.054 0.096
202603 -0.052 330.213 -0.052

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-9.31 mean?
Novavax (FRA:NVV1) has a E10 of €-9.31 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's E10 too high?
Novavax's current E10 is €-9.31. Overall, Novavax has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's E10 compare to MPLT and COAG?
Novavax's E10 of €-9.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current E10 is €-9.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (FRA:NVV1) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.26, compared to a current price of €8.02 — trading 146% above its estimated fair value. The current E10 is €-9.31. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Novavax (FRA:NVV1), the current E10 is €-9.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €8.02 is trading 146% above its estimated GF Value™ of €3.26. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • E10: €-9.31
  • GF Value™: €3.26 vs. price of €8.02 (146% above fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score

Get the complete analysis for FRA:NVV1

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.02
Price
€3.26
GF Value